These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21412935)

  • 21. Antimicrobial peptides as microbicidal contraceptives: prophecies for prophylactics--a mini review.
    Yedery RD; Reddy KV
    Eur J Contracept Reprod Health Care; 2005 Mar; 10(1):32-42. PubMed ID: 16036297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbicides to prevent heterosexual transmission of HIV: ten years down the road.
    van de Wijgert J; Coggins C
    BETA; 2002; 15(2):23-8. PubMed ID: 12064303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What does preexposure prophylaxis mean for treatment; what does treatment mean for preexposure prophylaxis?
    Venter WD
    Curr Opin HIV AIDS; 2016 Jan; 11(1):35-40. PubMed ID: 26545265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model for communitywide delivery of postexposure prophylaxis after potential sexual exposure to HIV.
    Roland ME
    Sex Transm Dis; 2007 May; 34(5):294-6. PubMed ID: 17308501
    [No Abstract]   [Full Text] [Related]  

  • 25. [Microbicides for preventing sexually transmitted infections: Current status and strategies for preclinical evaluation of new candidates].
    Fernández Romero JA; Gil PI; Ré V; Robbiani M; Paglini G
    Rev Argent Microbiol; 2014; 46(3):256-68. PubMed ID: 25444135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates.
    Herrera C; Armanasco N; García-Pérez J; Ziprin P; Olejniczak N; Alcamí J; Nuttall J; Shattock RJ
    AIDS; 2016 Apr; 30(7):1015-25. PubMed ID: 26854808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The promise and pitfalls of long-acting injectable agents for HIV prevention.
    Landovitz RJ; Kofron R; McCauley M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections.
    Nikolic DS; Garcia E; Piguet V
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):77-88. PubMed ID: 17266456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ARV-based HIV prevention for women - where we are in 2014.
    Mastro TD; Sista N; Abdool-Karim Q
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19154. PubMed ID: 25224614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postexposure prophylaxis for HIV following sexual exposure.
    Barber TJ; Benn PD
    Curr Opin HIV AIDS; 2010 Jul; 5(4):322-6. PubMed ID: 20543608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethical considerations regarding oral preexposure prophylaxis in HIV prevention trials.
    Sugarman J
    Curr Opin HIV AIDS; 2016 Jan; 11(1):109-15. PubMed ID: 26633642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decline in new HIV diagnoses among MSM in Melbourne.
    Chow EPF; Medland NA; Denham I; Wright EJ; Fairley CK
    Lancet HIV; 2018 Sep; 5(9):e479-e481. PubMed ID: 30215345
    [No Abstract]   [Full Text] [Related]  

  • 33. An overview of the relative risks of different sexual behaviours on HIV transmission.
    Dosekun O; Fox J
    Curr Opin HIV AIDS; 2010 Jul; 5(4):291-7. PubMed ID: 20543603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving preclinical models of HIV microbicide efficacy.
    Roan NR; Münch J
    Trends Microbiol; 2015 Aug; 23(8):445-7. PubMed ID: 26250616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Highlights of HIVR4P 2018.
    Zuccala E
    Lancet HIV; 2018 Dec; 5(12):e683. PubMed ID: 30527326
    [No Abstract]   [Full Text] [Related]  

  • 36. Microbicides for the prevention of sexually transmitted HIV infection.
    Karim QA; Baxter C
    Expert Rev Anti Infect Ther; 2013 Jan; 11(1):13-23. PubMed ID: 23428099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analytical Advances in the Ex Vivo Challenge Efficacy Assay.
    Richardson-Harman N; Parody R; Anton P; McGowan I; Doncel G; Thurman AR; Herrera C; Kordy K; Fox J; Tanner K; Swartz G; Dezzutti CS
    AIDS Res Hum Retroviruses; 2017 Apr; 33(4):395-403. PubMed ID: 27841671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbicide research: current and future directions.
    Ramjee G
    Curr Opin HIV AIDS; 2010 Jul; 5(4):316-21. PubMed ID: 20543607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Male engagement in women's microbicide use in Kenya: Navigating gender norms.
    Schuler SR; Bukusi E
    Health Care Women Int; 2017 May; 38(5):507-519. PubMed ID: 28273003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microbicides-emerging essential pillars of comprehensive HIV/AIDS prevention.
    Gaym A
    Ethiop Med J; 2006 Oct; 44(4):405-15. PubMed ID: 17370443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.